789 related articles for article (PubMed ID: 18978535)
1. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis.
Doenhoff MJ; Cioli D; Utzinger J
Curr Opin Infect Dis; 2008 Dec; 21(6):659-67. PubMed ID: 18978535
[TBL] [Abstract][Full Text] [Related]
2. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Doenhoff MJ; Hagan P; Cioli D; Southgate V; Pica-Mattoccia L; Botros S; Coles G; Tchuem Tchuenté LA; Mbaye A; Engels D
Parasitology; 2009 Nov; 136(13):1825-35. PubMed ID: 19281637
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility to praziquantel of male and female cercariae of praziquantel-resistant and susceptible isolates of Schistosoma mansoni.
Liang YS; Wang W; Dai JR; Li HJ; Tao YH; Zhang JF; Li W; Zhu YC; Coles GC; Doenhoff MJ
J Helminthol; 2010 Jun; 84(2):202-7. PubMed ID: 19765323
[TBL] [Abstract][Full Text] [Related]
4. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
Doenhoff MJ; Pica-Mattoccia L
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):199-210. PubMed ID: 16597202
[TBL] [Abstract][Full Text] [Related]
5. Schistosomiasis: from drug deployment to drug development.
Caffrey CR; Secor WE
Curr Opin Infect Dis; 2011 Oct; 24(5):410-7. PubMed ID: 21734570
[TBL] [Abstract][Full Text] [Related]
6. Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death.
Pica-Mattoccia L; Orsini T; Basso A; Festucci A; Liberti P; Guidi A; Marcatto-Maggi AL; Nobre-Santana S; Troiani AR; Cioli D; Valle C
Exp Parasitol; 2008 Jul; 119(3):332-5. PubMed ID: 18456260
[TBL] [Abstract][Full Text] [Related]
7. Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance.
Vale N; Gouveia MJ; Rinaldi G; Brindley PJ; Gärtner F; Correia da Costa JM
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264841
[TBL] [Abstract][Full Text] [Related]
8. Schistosomiasis: challenges for control, treatment and drug resistance.
Fenwick A; Webster JP
Curr Opin Infect Dis; 2006 Dec; 19(6):577-82. PubMed ID: 17075334
[TBL] [Abstract][Full Text] [Related]
9. The anthelmintic drug praziquantel activates a schistosome transient receptor potential channel.
Park SK; Gunaratne GS; Chulkov EG; Moehring F; McCusker P; Dosa PI; Chan JD; Stucky CL; Marchant JS
J Biol Chem; 2019 Dec; 294(49):18873-18880. PubMed ID: 31653697
[TBL] [Abstract][Full Text] [Related]
10. [Research progress of the evaluation methods on the resistance of schistosome to praziquantel].
Guo J; Guo JG
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Jun; 23(3):182-4. PubMed ID: 16300016
[No Abstract] [Full Text] [Related]
11. Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel.
Chienwichai P; Tipthara P; Tarning J; Limpanont Y; Chusongsang P; Chusongsang Y; Adisakwattana P; Reamtong O
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009706. PubMed ID: 34473691
[TBL] [Abstract][Full Text] [Related]
12. Schistosomiasis control: praziquantel forever?
Cioli D; Pica-Mattoccia L; Basso A; Guidi A
Mol Biochem Parasitol; 2014 Jun; 195(1):23-9. PubMed ID: 24955523
[TBL] [Abstract][Full Text] [Related]
13. Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
da Silva VBR; Campos BRKL; de Oliveira JF; Decout JL; do Carmo Alves de Lima M
Bioorg Med Chem; 2017 Jul; 25(13):3259-3277. PubMed ID: 28495384
[TBL] [Abstract][Full Text] [Related]
14. The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP.
Park SK; Marchant JS
Trends Parasitol; 2020 Feb; 36(2):182-194. PubMed ID: 31787521
[TBL] [Abstract][Full Text] [Related]
15. Modulation of the antioxidant defence in different developmental stages of Schistosoma mansoni by praziquantel and artemether.
El-Bassiouni EA; Helmy MH; Saad EI; El-Nabi Kamel MA; Abdel-Meguid E; Hussein HS
Br J Biomed Sci; 2007; 64(4):168-74. PubMed ID: 18236739
[TBL] [Abstract][Full Text] [Related]
16. Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives.
Nogueira RA; Lira MGS; Licá ICL; Frazão GCCG; Dos Santos VAF; Filho ACCM; Rodrigues JGM; Miranda GS; Carvalho RC; Nascimento FRF
Mol Biochem Parasitol; 2022 Nov; 252():111531. PubMed ID: 36375598
[TBL] [Abstract][Full Text] [Related]
17. Validation of sensitivity to praziquantel using Schistosoma mansoni worm muscle tension and Ca2+-uptake as possible in vitro correlates to in vivo ED50 determination.
William S; Botros S
Int J Parasitol; 2004 Jul; 34(8):971-7. PubMed ID: 15217736
[TBL] [Abstract][Full Text] [Related]
18. Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective?
Dissous C; Grevelding CG
Trends Parasitol; 2011 Feb; 27(2):59-66. PubMed ID: 20920890
[TBL] [Abstract][Full Text] [Related]
19. Use of fluorescent probes as a useful tool to identify resistant Schistosoma mansoni isolates to praziquantel.
Couto FF; Coelho PM; Araújo N; Kusel JR; Katz N; Mattos AC
Parasitology; 2010 Oct; 137(12):1791-7. PubMed ID: 20561394
[TBL] [Abstract][Full Text] [Related]
20. Could we expect new praziquantel derivatives? A meta pharmacometrics/pharmacoinformatics analysis of all antischistosomal praziquantel derivatives found in the literature.
da Silva VBR; Boucherle B; El-Methni J; Hoffmann B; da Silva AL; Fortune A; de Lima MDCA; Thomas A
SAR QSAR Environ Res; 2019 Jun; 30(6):383-401. PubMed ID: 31144535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
